co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage defects. Its customers include accident surgeons, orthopaedic surgeons, and neurosurgeons in clinics and specialised practices. The firms main product Spherox is a three-dimensional chondrocyte product used to treat articular cartilage defects in the knee with autologous cells by means of matrix-associated autologous chondrocyte transplantation. The company was founded in 1993 and is headquartered in Teltow, Germany.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company